Where Does Wall Street Think Arena Pharmaceuticals, Inc. (ARNA) Stock Will Go?

Thursday, March 03, 2022 02:44 PM | InvestorsObserver Analysts

Mentioned in this article

Where Does Wall Street Think Arena Pharmaceuticals, Inc. (ARNA) Stock Will Go?

InvestorsObserver is giving Arena Pharmaceuticals, Inc. (ARNA) an Analyst Rating Rank of 14, meaning ARNA is ranked higher by analysts than 14% of stocks. The average price target for ARNA is $93.875 and analyst’s rate the stock as a Buy.

Wall Street analysts are rating ARNA a Buy today. Find out what this means to you and get the rest of the rankings on ARNA!

See Full ARNA Report

Why are Analyst Ratings Important?

Analysts know the inner workings of the companies they follow better than anyone but the companies’ management. You can learn a lot about a company from studying the financial statements, but analysts ask questions on conference calls and understand the intricacies of each of the businesses they cover. Analysts understand how bad weather in one part of the world can disrupt supply chains, or disrupt shopping patterns. This lets traders make decisions before a quarterly report that could be worse than expected. InvestorsObserver aggregates the ratings of all the analysts covering a given stock, takes the average of those ratings and then percentile ranks the averages. That provides a level of granularity that is significantly better than just the three levels provided by traditional buy/hold/sell ratings.

What's Happening With Arena Pharmaceuticals, Inc. Stock Today?

Arena Pharmaceuticals, Inc. (ARNA) stock is lower by -0.2% while the S&P 500 is higher by 0.06% as of 2:44 PM on Thursday, Mar 3. ARNA is lower by -$0.19 from the previous closing price of $94.42 on volume of 433,552 shares. Over the past year the S&P 500 is higher by 14.90% while ARNA is higher by 28.62%. ARNA lost -$10.14 per share the over the last 12 months. Click Here to get the full Stock Report for Arena Pharmaceuticals, Inc. stock.